Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609134 | 1.00 | SRD5A1 (0.54) | SRD5A1CYP2C19CYP19A1SRD5A2CYP1B1 | |
| SCHEMBL7711721 | 0.79 | SRD5A1 (0.49) | SRD5A1CYP19A1SRD5A2CYP1B1G6PD | |
| SCHEMBL7711725 | 0.79 | SRD5A1 (0.49) | SRD5A1CYP19A1SRD5A2CYP1B1G6PD | |
| SCHEMBL7616969 | 0.78 | SRD5A1 (0.51) | SRD5A1CYP2C19CYP19A1SRD5A2 | |
| SCHEMBL7616961 | 0.78 | SRD5A1 (0.51) | SRD5A1CYP2C19CYP19A1SRD5A2 | |
| SCHEMBL7609770 | 0.78 | SRD5A1 (0.51) | SRD5A1CYP2C19CYP19A1SRD5A2 | |
| SCHEMBL7609766 | 0.78 | SRD5A1 (0.51) | SRD5A1CYP2C19CYP19A1SRD5A2 | |
| SCHEMBL3795654 | 0.77 | SRD5A1 (0.61) | SRD5A1CYP19A1G6PD | |
| SCHEMBL7617616 | 0.77 | SRD5A1 (0.61) | SRD5A1CYP19A1G6PD | |
| SCHEMBL8065395 | 0.76 | SRD5A1 (0.60) | SRD5A1CYP2C19CYP19A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0880540-B1 | 17-BETA-CYCLOPROPYL(AMINO/OXY) 4-AZA STEROIDS AS ACTIVE INHIBITORS OF TESTOSTERONE 5-ALPHA-REDUCTASE AND C17-20-LYASE | AVENTIS PHARMA INC (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6365597-B1 | FOR THERAPY OF ANDROGEN AND ESTROGEN MEDIATED DISORDERS, INCLUDING BENIGN PROSTATIC HYPERPLASIA, ANDROGEN MEDIATED PROSTATE CANCER, ESTROGEN MEDIATED BREAST CANCER AND ACNE | AVENTIS PHARMACEUTICALS INC. | 2002-04-02 | — | — | US | disclosed |